A group of Colorado lawmakers abandoned a controversial bill that would have required exemptions for rare disease drugs on a state board setting caps for medicine costs. They introduced a revised version, directing the Prescription Drug Affordability Board to consider different uses of medicines with orphan designations, aiming to give more voice to patients. The original bill aimed to prevent loss of access to rare disease drugs if companies cease sales. The pharmaceutical industry argues that high prices on these drugs reflect significant investments in testing and development for small patient populations. Another state entity, the Rare Disease Advisory Council, would review such drugs under the new legislation.
Source link
Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps
